Trials / Recruiting
RecruitingNCT07177339
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study of the Efficacy and Safety of Early Depemokimab Initiation as add-on Treatment in COPD Patients With Type 2 Inflammation
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,196 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Depemokimab | Depemokimab will be administered. |
| DRUG | Placebo | Matching placebo will be administered. |
Timeline
- Start date
- 2025-10-20
- Primary completion
- 2029-11-02
- Completion
- 2029-12-14
- First posted
- 2025-09-17
- Last updated
- 2025-11-25
Locations
6 sites across 2 countries: United States, China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07177339. Inclusion in this directory is not an endorsement.